CONGENITAL CHOLESTEATOMA

A Comprehensive Essay for 50 Marks

1. DEFINITION

1. White, pearly mass medial to an intact tympanic membrane
2. Normal pars flaccida and pars tensa
3. No prior history of otorrhoea, perforation, or otological surgery
4. No history of prior otitis media (debated — some authors now allow past OM)

2. HISTORICAL BACKGROUND

3. EPIDEMIOLOGY

• Congenital cholesteatoma accounts for 2–5% of all cholesteatomas in general otological practice
• In the pediatric population, CC represents approximately 20–30% of all pediatric cholesteatomas
• Annual incidence: approximately 3–15 per 100,000 children
• Sex: Male predominance (M:F ≈ 3:1)
• Age of presentation: Most commonly between 3–5 years (range: 6 months to teenage years)
• Side: Unilateral > bilateral (bilateral cases reported in twins — suggesting a genetic component)
• Site: Anterior-superior quadrant (most common, ~70%), posterior quadrant, or multiple quadrants

4. EMBRYOLOGY & THEORIES OF PATHOGENESIS

4.1 Michaels' Epidermoid Formation (EF) Theory (Most Widely Accepted)

• This EF normally undergoes programmed apoptosis and disappears by the 33rd week of gestation
• Failure of involution of this EF leads to persistence and subsequent expansion, forming CC
• This explains the predominant location of CC in the anterior-superior quadrant

┌─────────────────────────────────────────────────────┐
│         MICHAELS' EPIDERMOID FORMATION THEORY        │
│                                                      │
│  10-33 wks gestation                                 │
│  Epidermoid Formation (EF) appears                   │
│  in anterior-superior middle ear cleft               │
│           │                                          │
│    ┌──────┴──────┐                                   │
│    ↓             ↓                                   │
│ NORMAL        FAILURE OF                             │
│ Involution    Involution                             │
│ (apoptosis)   (persistence)                          │
│    ↓             ↓                                   │
│ No disease    CONGENITAL                             │
│               CHOLESTEATOMA                          │
└─────────────────────────────────────────────────────┘

4.2 Other Theories

4.3 Genetic Basis

• Bilateral CC and CC in identical twins have been reported (Al Balushi et al.; Marchioni et al., IJPO 2017)
• A specific genetic mutation has not yet been identified
• Familial clustering suggests a heritable component — area of active research

5. SITES / LOCATION

LOCATIONS OF CONGENITAL CHOLESTEATOMA
(in order of frequency)

1. MIDDLE EAR (Most Common)
   ├── Anterior-superior quadrant (~70%)
   ├── Posterior quadrant
   └── Entire middle ear

2. PETROUS APEX

3. MASTOID

4. CEREBELLOPONTINE ANGLE

5. EXTERNAL AUDITORY CANAL (rare)

6. INTRACRANIAL (very rare)

6. PATHOLOGY

6.1 Macroscopy

• Pearly-white, smooth, round, glistening cystic mass behind an intact TM
• Also called the "keratin pearl" or "white pearl"
• Cyst wall is thin and filled with laminated keratin flakes

6.2 Microscopy

1. Outer layer (Matrix): Stratified squamous epithelium — the "engine" of cholesteatoma
2. Middle layer (Perimatrix): Fibrous connective tissue with inflammatory cells, fibrocytes
3. Inner layer: Desquamated, laminated keratin debris (the "content")

6.3 Mechanism of Bone Erosion

MECHANISM OF BONE EROSION IN CHOLESTEATOMA

Squamous Epithelium (Matrix)
        │
        ↓ Produces
Cytokines: IL-1, IL-6, TNF-α
Enzymes:  Collagenase, MMPs (Matrix Metalloproteinases)
          Cathepsins, Acid Phosphatase
        │
        ↓ Stimulate
Osteoclast Activation
        │
        ↓
BONE EROSION
(Ossicles → Tegmen → Labyrinth → Facial Canal)

• MMPs (MMP-2, MMP-9) — most important
• RANKL/RANK/OPG pathway — regulates osteoclastogenesis
• EGF receptor signalling — promotes epithelial hyperproliferation
• TGF-β — promotes fibrosis in perimatrix

7. CLINICAL FEATURES

7.1 Symptoms

CLINICAL PRESENTATION FLOWCHART

Child (age 3-5 yrs), male predominance
No prior history of:
  • Ear discharge (otorrhoea)
  • Tympanic membrane perforation
  • Ear surgery
  • Chronic otitis media
        │
        ↓
PRESENTING SYMPTOMS
┌────────────────┬────────────────────┬───────────────┐
│ Hearing loss   │ Incidental finding │ Ear pain/     │
│ (Conductive)   │ (on routine exam)  │ fullness      │
│ (Most common   │ (common in early   │ (uncommon)    │
│  symptom)      │  stage I)          │               │
└────────────────┴────────────────────┴───────────────┘
         │
Late/Complicated Cases:
  • Facial nerve palsy
  • Vertigo/sensorineural hearing loss
  • Otorrhoea (if TM perforates)
  • Meningitis / intracranial complications

7.2 Signs

• White, pearly mass behind an intact tympanic membrane — pathognomonic
• Typically in the anterior-superior quadrant
• Tympanic membrane is translucent; the mass shines through
• No perforation, no retraction pocket, no discharge

8. STAGING SYSTEM (Potsic et al., 2002)

╔══════════════════════════════════════════════════════════════╗
║           POTSIC STAGING SYSTEM FOR CONGENITAL               ║
║                    CHOLESTEATOMA (2002)                      ║
╠═══════╦══════════════════════════════════╦══════════════════╣
║ STAGE ║ EXTENT                           ║ RESIDUAL RISK    ║
╠═══════╬══════════════════════════════════╬══════════════════╣
║   I   ║ Single quadrant, no ossicular    ║ Low              ║
║       ║ involvement                      ║ (<5%)            ║
╠═══════╬══════════════════════════════════╬══════════════════╣
║  II   ║ Multiple quadrants, no ossicular ║ Moderate         ║
║       ║ involvement                      ║ (~15%)           ║
╠═══════╬══════════════════════════════════╬══════════════════╣
║  III  ║ Ossicular involvement, no        ║ High             ║
║       ║ mastoid extension                ║ (~33%)           ║
╠═══════╬══════════════════════════════════╬══════════════════╣
║  IV   ║ Mastoid extension                ║ Very High        ║
║       ║                                  ║ (~67%)           ║
╚═══════╩══════════════════════════════════╩══════════════════╝

9. INVESTIGATIONS

9.1 Audiological Assessment

• Pure Tone Audiometry (PTA): Conductive hearing loss — most common finding
  • Air-Bone Gap (ABG): typically 20–40 dB
  • Sensorineural component suggests labyrinthine involvement
• Tympanometry: Type A or As curve (if intact TM) — not Type B unless effusion coexists
• BERA (ABR): In young/uncooperative children

9.2 Radiology

• Investigation of choice for surgical planning
• Demonstrates:
  • Soft tissue mass in middle ear (anterior-superior quadrant)
  • Ossicular erosion — incus most commonly affected (lenticular process)
  • Scutum erosion (Prussak's space involvement — more in acquired)
  • Mastoid involvement (Stage IV)
  • Tegmen or labyrinthine fistula (advanced disease)

• Superior for soft tissue characterization and residual/recurrent disease
• Non-EPI DWI (Diffusion-Weighted Imaging): Investigation of choice for detecting residual cholesteatoma after surgery
  • CC shows high signal on DWI + low signal on ADC map (restricted diffusion) — pathognomonic
  • Sensitivity 90–100%, Specificity 90–100% for residual CC
• T1: Hypointense; T2: Hyperintense

IMAGING ALGORITHM FOR CONGENITAL CHOLESTEATOMA

Clinical suspicion
(White mass behind intact TM)
        │
        ↓
HRCT Temporal Bone
(Extent, ossicular erosion, surgical planning)
        │
        ↓
MRI (Non-EPI DWI)
(Soft tissue detail, pre-op characterization)
        │
        ↓
POST-OPERATIVE SURVEILLANCE:
MRI Non-EPI DWI at 12–18 months
(Detect residual / recurrent disease)
        │
    ┌───┴───┐
  DWI +ve  DWI -ve
    │         │
Second-look  Continue
surgery      surveillance

10. DIFFERENTIAL DIAGNOSIS

DIFFERENTIAL DIAGNOSIS OF WHITE MASS BEHIND INTACT TM

┌─────────────────────┬───────────────────────────────────────────┐
│ CONDITION           │ DISTINGUISHING FEATURES                   │
├─────────────────────┼───────────────────────────────────────────┤
│ Congenital          │ Pearly, anterior-superior, DWI restricted │
│ Cholesteatoma       │ No discharge, no perforation              │
├─────────────────────┼───────────────────────────────────────────┤
│ Cholesterol         │ Amber/blue TM; T1 bright on MRI           │
│ Granuloma           │ (no DWI restriction)                      │
├─────────────────────┼───────────────────────────────────────────┤
│ Middle Ear          │ Fluid level, bilateral, resolves          │
│ Effusion (OME)      │ with decongestants                        │
├─────────────────────┼───────────────────────────────────────────┤
│ Glomus Tympanicum   │ Pulsatile, red/pink, posterior-inferior   │
├─────────────────────┼───────────────────────────────────────────┤
│ Aberrant ICA        │ Pulsatile, do NOT biopsy, CT angiography  │
├─────────────────────┼───────────────────────────────────────────┤
│ High Jugular Bulb   │ Blue mass, inferior quadrant              │
├─────────────────────┼───────────────────────────────────────────┤
│ Tympanosclerosis    │ History of prior OM/surgery, chalky white │
├─────────────────────┼───────────────────────────────────────────┤
│ Facial Nerve        │ Along CN VII course, enhances on MRI      │
│ Schwannoma          │                                           │
└─────────────────────┴───────────────────────────────────────────┘

11. MANAGEMENT

11.1 Overview

MANAGEMENT FLOWCHART — CONGENITAL CHOLESTEATOMA

Diagnosis Confirmed
(White mass + Intact TM + No prior OM/surgery)
        │
        ↓
STAGING (Potsic system: HRCT + MRI)
        │
        ├──────────────────┬─────────────────┬──────────────┐
        │                  │                 │              │
      Stage I           Stage II          Stage III     Stage IV
        │                  │                 │              │
   Transcanal          Transcanal/       Mastoid +     Canal Wall
   approach;          Postauricular;    Posterior      Down (CWD) OR
   Myringotomy +      Tympanoplasty     Tympanotomy;  Canal Wall Up
   Excision                             Ossiculoplasty (CWU) +
                                        if needed     Second-Look
        │
        ↓
COMPLETE EXCISION (PRIMARY GOAL)
        │
        ↓
HEARING RECONSTRUCTION
(Ossiculoplasty / TORP / PORP as required)
        │
        ↓
SECOND-LOOK SURGERY (if Stage III/IV)
OR
MRI NON-EPI DWI at 12–18 months post-op

11.2 Surgical Approaches

• For early-stage CC (Stage I, small Stage II)
• Tympanomeatal flap raised; CC excised completely
• Increasingly performed endoscopically (TEES — Transcanal Endoscopic Ear Surgery)

• For larger Stage II and Stage III lesions
• Better visualisation of the entire middle ear

• Stage III–IV; preserves anatomy
• Higher residual/recurrence rate — second-look surgery mandatory at 12–18 months

• Extensive Stage IV with large-scale destruction
• Lower recurrence but meatoplasty needed; cavity care required

11.3 Ossiculoplasty

• Intact ossicular chain: Preserve during excision
• Incus erosion: PORP (Partial Ossicular Replacement Prosthesis) — connects stapes to malleus handle
• Stapes superstructure absent: TORP (Total Ossicular Replacement Prosthesis)
• Materials: Autologous cartilage/cortical bone or titanium/hydroxyapatite prostheses

11.4 Second-Look Surgery vs. MRI Surveillance

SECOND-LOOK / SURVEILLANCE ALGORITHM

Post-operative (Stage III/IV)
        │
        ↓
MRI Non-EPI DWI at 12–18 months
        │
   ┌────┴────┐
DWI +ve   DWI -ve
  │           │
Second-look   Annual clinical
surgery        review + repeat
(Revision      MRI at 3 years
tympanomastoid)

12. COMPLICATIONS

COMPLICATIONS OF UNTREATED / ADVANCED CONGENITAL CHOLESTEATOMA

INTRATEMPORAL                    INTRACRANIAL
─────────────────────            ──────────────────────────
• Conductive hearing loss        • Extradural abscess
• Sensorineural hearing loss     • Subdural abscess
  (labyrinthine fistula)         • Meningitis
• Facial nerve palsy             • Brain abscess
  (canal dehiscence)             • Lateral sinus thrombophlebitis
• Labyrinthitis                  • Otitic hydrocephalus
• Mastoiditis
• Petrous apicitis
  (Gradenigo's syndrome)

13. COMPARISON WITH ACQUIRED CHOLESTEATOMA

┌────────────────────┬──────────────────────────┬──────────────────────────┐
│ FEATURE            │ CONGENITAL               │ ACQUIRED                 │
├────────────────────┼──────────────────────────┼──────────────────────────┤
│ Age                │ 3–5 years                │ 10–15 years (pedi);      │
│                    │                          │ any age (adult)          │
├────────────────────┼──────────────────────────┼──────────────────────────┤
│ TM integrity       │ INTACT (by definition)   │ Perforated / retraction  │
├────────────────────┼──────────────────────────┼──────────────────────────┤
│ Prior OM/otorrhoea │ Absent                   │ Usually present          │
├────────────────────┼──────────────────────────┼──────────────────────────┤
│ Location           │ Anterior-superior ME     │ Pars flaccida (attic) or │
│                    │                          │ pars tensa (posterior)   │
├────────────────────┼──────────────────────────┼──────────────────────────┤
│ Pathogenesis       │ Failure of EF involution │ Retraction, basal cell   │
│                    │ (Michaels' theory)       │ hyperplasia, metaplasia  │
├────────────────────┼──────────────────────────┼──────────────────────────┤
│ Macroscopy         │ Pearl-like, well-defined │ Irregular, often with    │
│                    │ cyst                     │ granulations / discharge │
├────────────────────┼──────────────────────────┼──────────────────────────┤
│ Presentation       │ Often incidental / CHL   │ Foul-smelling discharge, │
│                    │                          │ CHL, pain                │
├────────────────────┼──────────────────────────┼──────────────────────────┤
│ Prognosis          │ Better (if early stage)  │ Higher recurrence rate   │
└────────────────────┴──────────────────────────┴──────────────────────────┘

14. RECENT ADVANCES

14.1 Endoscopic Ear Surgery (TEES)

• Transcanal endoscopic approach with zero-degree and 45-degree endoscopes
• Advantages: Single port, improved visualisation of anterior recesses (sinus tympani, facial recess), no postauricular scar
• Increasingly preferred for Stage I–II CC
• Allows complete excision without canal wall down surgery in early stages
• Recent literature: Badr-el-Dine M; Marchioni D, Presutti L

14.2 Non-Echo Planar DWI MRI (Non-EPI DWI)

• Has revolutionised post-operative surveillance
• High sensitivity (>90%) and specificity for detecting residual keratin as small as 3–5 mm
• PROPELLER/BLADE DWI sequences further improve accuracy
• May predict need for second-look surgery without surgical exploration
• Dubrulle F et al.; Lingam RK et al.

14.3 Molecular Pathogenesis

• RANKL/OPG ratio — elevated in CC; drives osteoclast activation
• MMP-2 and MMP-9 — major enzymes responsible for ossicular erosion
• Ki-67 index — CC has lower proliferative index than acquired cholesteatoma
• Notch signalling pathway — implicated in epithelial hyperproliferation
• Potential future target for medical/biological therapy to arrest growth

14.4 Genetic Research

• Reports of familial CC and bilateral CC in identical twins support a genetic susceptibility
• Genome-wide association studies (GWAS) ongoing — no confirmed mutation yet

14.5 Otoendoscopy (Office-based)

• High-definition otoscopy/otoendoscopy improves early detection of small CC
• Leukocoria of the ear analogy — white reflex behind TM as a screening finding

14.6 Robot-Assisted Ear Surgery

• Experimental robotic platforms (e.g., RobOtol) are being evaluated for minimally invasive middle ear surgery — potential future application for CC

14.7 PROPELLER/HASTE MRI Protocols

• Latest non-EPI DWI protocols with sub-millimetre resolution detect even tiny residual pearls
• Reduces the need for routine second-look surgery in carefully selected cases

15. PERSPECTIVES FROM MAJOR TEXTBOOKS

Scott Brown's Otorhinolaryngology Head & Neck Surgery

• Emphasises that CC arises from persistence of embryological epidermoid cell rests (Michaels' EF)
• Describes the diagnostic triad: white pearly mass + intact TM + no prior OM
• Recommends CWU approach for most cases with planned second-look at 12–18 months
• Stresses importance of complete matrix removal — leaving matrix behind is the most common cause of recurrence

Cummings Otolaryngology Head and Neck Surgery

• States: "Acquired cholesteatoma is much more common than congenital cholesteatoma, even in children"
• Documents Potsic staging and its correlation with residual disease risk
• Notes smaller mastoid volume in CC patients compared to controls — suggests a shared developmental predisposition
• Emphasises that non-EPI DWI MRI has transformed follow-up protocols
• References bilateral CC in twins as evidence for potential genetic basis

Stell & Maran's Head & Neck Surgery

• Describes CC as arising from sequestered ectodermal inclusions during embryological development
• Emphasises that surgical timing is important — early surgery prevents bone destruction and preserves hearing
• Documents the "inside-out" spread pattern — CC expands concentrically from its origin

Dhingra's Diseases of Ear, Nose & Throat

• Classic Indian ENT reference widely used in RGUHS curriculum
• Defines CC with Levenson's criteria
• Lists Michaels' EF theory as the most accepted
• Describes otoscopic appearance as a "white pearl" — distinguishing CC from OME
• Stages: Anterior-superior (most common) → posterior → ossicular involvement → mastoid

Hazarika's Textbook of Ear, Nose & Throat

• Emphasises CC in the Indian context — often presents late due to diagnostic delay
• Notes that CHL in a child with an intact TM should always raise suspicion of CC
• Discusses the role of HRCT temporal bone as the primary investigation
• Advocates CWU mastoidectomy with second-look for advanced cases

Zakir Hussain (ENT Reference)

• Documents CC as a keratoma with no cholesterol or fat content despite its name
• Stresses histological features: stratified squamous epithelium + fibrous perimatrix + keratinous content
• Includes CC in differential diagnosis of conductive hearing loss in children
• Advocates that all intact TM with CHL in children must be investigated with HRCT

KJ Lee's Essential Otolaryngology

• Lists CC under pediatric otology
• Notes anterior-superior quadrant predilection based on Michaels' fetal temporal bone studies
• Provides surgical decision-making guidance based on extent of disease

16. SUMMARY FLOWCHART — COMPLETE OVERVIEW

╔═══════════════════════════════════════════════════════════════════╗
║          CONGENITAL CHOLESTEATOMA — MASTER FLOWCHART             ║
╠═══════════════════════════════════════════════════════════════════╣
║                                                                   ║
║  EMBRYOLOGY                                                       ║
║  Failure of involution of Michaels' Epidermoid Formation (EF)    ║
║  at 10-33 weeks gestation (anterior-superior tympanum)           ║
║           │                                                       ║
║           ↓                                                       ║
║  PATHOLOGY                                                        ║
║  Keratinizing squamous cyst → Bone erosion via MMPs/RANKL        ║
║           │                                                       ║
║           ↓                                                       ║
║  CLINICAL                                                         ║
║  Child, male, age 3-5 yrs; white pearly mass, intact TM          ║
║  CHL (most common symptom) | No otorrhoea | No prior OM          ║
║           │                                                       ║
║           ↓                                                       ║
║  INVESTIGATIONS                                                   ║
║  PTA (CHL) → HRCT temporal bone → MRI Non-EPI DWI               ║
║           │                                                       ║
║           ↓                                                       ║
║  STAGING (Potsic 2002)                                           ║
║  Stage I → II → III → IV (67% residual risk)                    ║
║           │                                                       ║
║           ↓                                                       ║
║  SURGERY (ONLY TREATMENT)                                        ║
║  Transcanal/Endoscopic (early) | CWU/CWD Mastoidectomy (late)   ║
║  + Ossiculoplasty (if needed)                                    ║
║           │                                                       ║
║           ↓                                                       ║
║  SURVEILLANCE                                                     ║
║  MRI Non-EPI DWI at 12-18 months                                ║
║  +/- Second-look surgery (Stage III/IV or DWI positive)         ║
║           │                                                       ║
║           ↓                                                       ║
║  GOAL: Dry, hearing ear; prevent complications                   ║
╚═══════════════════════════════════════════════════════════════════╝

17. CONCLUSION

Key References

1. Michaels L. An epidermoid formation in the developing middle ear: possible source of cholesteatoma. J Otolaryngol. 1986;15(3):169-174.
2. Levenson MJ et al. Congenital cholesteatoma. Arch Otolaryngol. 1989;115(1):547-553.
3. Potsic WP et al. A staging system for congenital cholesteatoma. Arch Otolaryngol Head Neck Surg. 2002;128(9):1009–1012.
4. Cummings Otolaryngology Head and Neck Surgery, 7th ed. Cummings CW et al. Elsevier.
5. Dhingra PL. Diseases of Ear, Nose and Throat. 7th ed. Elsevier.
6. Hazarika P et al. Textbook of ENT & Head Neck Surgery.
7. Scott-Brown's Otorhinolaryngology, Head and Neck Surgery, 8th ed. Gleeson M et al.
8. Stell & Maran's Head and Neck Surgery.
9. Marchioni D et al. Bilateral congenital cholesteatoma. IJPO. 2017;99:146–151.
10. Huisman MA et al. MMP and RANKL in cholesteatoma. Otol Neurotol. 2008.
11. Lingam RK et al. Non-echo-planar DWI MRI for cholesteatoma surveillance. Clin Radiol. 2013.

Note on image generation: The generate_image tool (for custom diagrams) has reached its monthly plan limit. The flowcharts above are provided as text-based ASCII diagrams. To access additional generated diagrams, please upgrade your subscription plan. The clinical photographs from the medical literature (Figs. 1–3 above) are sourced from peer-reviewed publications and illustrate all key features discussed.